Physician profile
Jeffrey Heimer
NPI 1972553873
$6,429.94
in general payments reported to CMS, 2019-2025
22 companies · $411 in 2025
The $411 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $297 · 2021: $409 · 2022: $383 · 2023: $4,161 · 2024: $393 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,763 · Food and Beverage: $1,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,762.50 |
| Food and Beverage | $1,202.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim International Gmbh | $3,762.50 | 2023 | |
| Sun Pharmaceutical Industries INC. | $363.52 | 2019-2025 | Cequa, Xelpros |
| Alcon Vision LLC | $355.62 | 2019-2025 | Clareon, Eysuvis, Argos |
| Bausch & Lomb Americas INC. | $271.68 | 2022-2025 | Miebo, Envista Mx60 Iol, Vyzulta |
| Abbvie INC. | $271.58 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $258.04 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $220.08 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $181.37 | 2019-2021 | |
| Allergan, INC. | $180.79 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $92.27 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $77.96 | 2022-2025 | Tyrvaya |
| Biotissue Holdings INC. | $65.22 | 2019-2025 | |
| Ocular Therapeutix, INC. | $56.97 | 2024-2025 | Dextenza |
| Thea Pharma INC. | $51.94 | 2023-2025 | Iyuzeh |
| Glaukos Corporation | $41.77 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $37.72 | 2021-2025 | Tecnis Simplicity |
| Shire North American Group INC | $36.61 | 2019 | |
| Amgen INC. | $27.96 | 2024 | Tepezza |
| Horizon Therapeutics Plc | $24.03 | 2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $18.71 | 2021 | |
| Carl Zeiss Meditec Ag | $17.20 | 2020 | |
| Dompe US, INC. | $16.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Heimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.